glp-1 kaiser 📌 Starting January 1, 2025, Permanente will be making adjustments to the coverage of drugs and other Anti-Obesity Medications (AOMs) in California commercial plans. For members with a BMI less kaiser permanente glp-1 coverage policy

Let our values Patients, Science, Passion drive our decisions to success

This was 1.5-fold higher than the rate in 2023, which was 9.9 prescriptions per 100,000 adolescents

The target is well-validated mechanistically

Key highlights: Once-daily oral administration No food or water restrictions No injections required ~12% mean weight loss in Phase 3 trials Improvements in cardiometabolic risk markers Indication: Approved for adults with obesity, or overweight individuals with weight-related comorbidities, alongside reduced-calorie diet and increased physical activity

: ( 130 100 ) ( 50 100 ) ( 40 100 ) ( 20 100 )